THE-630 is a small molecule commercialized by Theseus Pharmaceuticals, with a leading Phase II program in Gastrointestinal Stromal Tumor (GIST). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of THE-630’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for THE-630 is expected to reach an annual total of $73 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

THE-630 Overview

THE-630 is under development for the treatment of refractory KIT-mutant gastrointestinal stromal tumors (GIST). It is administered by oral route. The drug candidate is a next-generation, pan-variant proto oncogene c Kit (KIT) inhibitor.

Theseus Pharmaceuticals Overview

Theseus Pharmaceuticals is a biopharmaceutical company that develops and discovers therapies to overcome treatment-resistant cancer mutations. The company focuses on developing pan-variant tyrosine kinase inhibitors (TKIs) through its products. Its product pipeline includes THE-630, a KIT inhibitor for treatment of gastrointestinal stromal tumors (GIST); and fourth generation epidermal growth factor receptor (EGFR) inhibitor to address C797S-mediated resistance to first or later line osimertinib treatment of non-small cell lung cancer (NSCLC). The company is also evaluating several potential oncogene targets inhibitors for areas of unmet clinical needs. Theseus is headquartered in Cambridge, Massachusetts, the US.

The operating loss of the company was US$27.3 million in FY2021, compared to an operating loss of US$6.8 million in FY2020. The net loss of the company was US$27.3 million in FY2021, compared to a net loss of US$12 million in FY2020.

For a complete picture of THE-630’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.